The controversial project attracted protesters, and some were kicked out of the meeting. City leaders approved a building permit for the AI center and blocked Fargo's move to annex the site. Applied ...

Gross domestic product rebounded in the spring after contracting at the start of the year, but consumer spending remained weak. By Ben Casselman Economic growth softened in the first half of the year, ...

Data Formulator enables users to iterate with AI to create rich data visualizations. Users define their visualization goals using blended user interface interactions and natural language inputs, while ...

On Tuesday, OpenAI announced a partnership with Oracle to develop 4.5 gigawatts of additional data center capacity for its Stargate AI infrastructure platform in the US. The expansion, which ...

See how to query documents using natural language, LLMs, and R—including dplyr-like filtering on metadata. Plus, learn how to use an LLM to extract structured data for text filtering. One of the ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. This paper presents ZacrosTools, a free and open-source Python library designed to ...

In the first six months of the Trump administration’s push for mass deportations, more than half of the U.S. Immigration and Customs Enforcement civil immigration arrests in San Diego and Imperial ...

This Python project automates the process of working with multiple Excel files. It reads Excel sheets from a folder, removes duplicates, combines them into a single clean dataset, saves the result to ...

Have you ever found yourself wrestling with Excel formulas, wishing for a more powerful tool to handle your data? Or maybe you’ve heard the buzz about Python in Excel and wondered if it’s truly the ...

Across America today, the sounds of unrest—riots, division, and violence—echo through our streets and flood our screens. We witness the destruction, the hatred, the confusion, and too often, we ...

Xilio Therapeutics reports 26% response rate for vilastobart and atezolizumab in metastatic MSS CRC patients, with favorable safety profile. Xilio Therapeutics has reported promising results from its ...